Outcomes of digoxin vs. beta blocker in atrial fibrillation: report from ESC-EHRA EORP AF Long-Term General Registry
| Autor: | Ding, Wern Yew, Boriani, Giuseppe, Marin, Francisco, Blomström-Lundqvist, Carina, Potpara, Tatjana S., Fauchier, Laurent, Lip, Gregory Y. H., Joensen, A. Marni, Gammelmark, A., Rasmussen, L. Hvilsted, Dinesen, P., Riahi, S., Venø, S. Krogh, Sorensen, B., Korsgaard, A., Andersen , K., Hellum, C. Fragtrup |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Quality of life
medicine.medical_specialty Registry Digoxin Rate control medicine.drug_class Permanent AF Adrenergic beta-Antagonists Heart failure 030204 cardiovascular system & hematology Digoxin/adverse effects 03 medical and health sciences 0302 clinical medicine Internal medicine EORP-AF Atrial Fibrillation medicine CKD Humans Pharmacology (medical) 030212 general & internal medicine Registries Mortality Beta blocker Hospitalizations Adrenergic beta-Antagonists/adverse effects business.industry Incidence (epidemiology) Confounding Atrial fibrillation medicine.disease 3. Good health Cardiology Quality of Life Cardiology and Cardiovascular Medicine business Atrial Fibrillation/complications Kidney disease medicine.drug |
| Zdroj: | Ding, W Y, Boriani, G, Marin, F, Blomström-Lundqvist, C, Potpara, T S, Fauchier, L, Lip, G Y H, ESC-EHRA EORP-AF Long-Term General Registry Investigators, Joensen, A M, Gammelmark, A, Rasmussen, L H, Dinesen, P, Riahi, S, Venø, S K, Sorensen, B, Korsgaard, A, Andersen, K & Hellum, C F 2022, ' Outcomes of digoxin vs. beta blocker in atrial fibrillation : report from ESC-EHRA EORP-AF Long-Term General Registry ', European heart journal. Cardiovascular pharmacotherapy, vol. 8, no. 4, pvab076, pp. 372–382 . https://doi.org/10.1093/ehjcvp/pvab076 |
| ISSN: | 2055-6845 |
| DOI: | 10.1093/ehjcvp/pvab076 |
| Popis: | Aims The safety of digoxin therapy in atrial fibrillation (AF) remains ill-defined. We aimed to evaluate the effects of digoxin over beta-blocker therapy in AF. Methods and results Patients with AF who were treated with either digoxin or a beta blocker from the ESC–EHRA EORP AF (European Society of Cardiology–European Heart Rhythm Association EURObservational Research Programme Atrial Fibrillation) General Long-Term Registry were included. Outcomes of interest were all-cause mortality, cardiovascular (CV) mortality, non-CV mortality, quality of life, and number of patients with unplanned hospitalizations. Of 6377 patients, 549 (8.6%) were treated with digoxin. Over 24 months, there were 550 (8.6%) all-cause mortality events and 1304 (23.6%) patients with unplanned emergency hospitalizations. Compared to beta blocker, digoxin therapy was associated with increased all-cause mortality [hazard ratio (HR) 1.90 (95% confidence interval, CI, 1.48–2.44)], CV mortality [HR 2.18 (95% CI 1.47–3.21)], and non-CV mortality [HR 1.68 (95% CI 1.02–2.75)] with reduced quality of life [health utility score 0.555 (±0.406) vs. 0.705 (±0.346), P Conclusion Poor outcomes related to the use of digoxin over beta-blocker therapy in terms of excess mortality and reduced quality of life are associated with the presence of other risk factors rather than digoxin per se. The choice of digoxin or beta-blocker therapy had no influence on the incidence of unplanned hospitalizations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|